Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A drug-drug interaction (DDI) study of ASC42

Next Previous
Trial Profile

A drug-drug interaction (DDI) study of ASC42

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASC 42 (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Adverse reactions
  • Sponsors Gannex Pharma

Most Recent Events

  • 13 Jun 2022 New trial record
  • 08 Jun 2022 According to a Gannex media release, FDA enables Gannex to complete a critical drug-drug interaction (DDI) study to support upcoming Phase III trials in China, the U.S. and European Union. The company has received U.S. FDA clearance for ASC42, to initiate a drug-drug interaction (DDI) study which inturn will support upcoming Phase III clinical trials in China, the U.S. and European Union for treatment of primary biliary cholangitis (PBC).
  • 08 Jun 2022 According to a Gannex media release, the company expects to complete this DDI study at the beginning of Q4, 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top